United States Market for Psoriatic Arthritis Pharmacotherapy
United States Market for Psoriatic Arthritis Pharmacotherapy
Availability of Novel Therapies Anticipated to Prompt Fresh Growth
RELEASE DATE
29-Jun-2012
29-Jun-2012
REGION
North America
North America
Research Code: NB3A-01-00-00-00
SKU: HC02232-NA-MR_07974
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
HC02232-NA-MR_07974
Description
This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as add-on therapy to background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).
Table of Contents
Research Service
- Executive Summary
- Market Overview
Psoriatic Arthritis Pharmacotherapeutics Market
- External Challenges: Drivers and Restraints
- Forecast and Trends
- Demand Analysis
- Market Share and Competitive Analysis
United States Market for Psoriatic Arthritis Pharmacotherapeutics: Analysis by Market Segment
- TNF Inhibitor Segment
- Non-TNF Biologics Segment
- Novel Oral DMARDs Segment
The Last Word
- Three Big Predictions
Appendix
- Appendix
Popular Topics
This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as add-on therapy to background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).
No Index | Yes |
---|---|
Podcast | No |
Author | Deborah Toscano |
Industries | Healthcare |
WIP Number | NB3A-01-00-00-00 |
Is Prebook | No |